What is Citigroup's price target for THC?

Citigroup's latest stated price target for Tenet Healthcare Corporation (THC) is $96, from its action on Jan 10, 2022.

What is Citigroup's rating on THC?

Citigroup rates THC Buy, a bullish rating, as of Jan 10, 2022.

When did Citigroup last change its view on THC?

On Jan 10, 2022, Citigroup resumes coverage at Buy, price target $91 to $96.

Citigroup THC price target and rating history

Tenet Healthcare Corporation (THC) · Health Care

Citigroup rates Tenet Healthcare Corporation (THC) Buy with a $96 price target, as of its latest action on Jan 10, 2022. It has published 3 rating actions on THC since July 2021, including 0 upgrades and 0 downgrades.

Current rating: Buy
Price target: $96
Median target, all firms: Too few
Actions on THC: 3

Citigroup price target on THC

Citigroup price target on THC, each point a stated target, July 2021 to January 2022.

Every Citigroup rating on THC

Jan 10, 2022
ResumeCitigroup resumes coverage at Buy, price target $91 to $96
Oct 25, 2021
ReiterateCitigroup raises its price target to $91 from $88, keeps Buy
Jul 23, 2021
ResumeCitigroup resumes coverage at Buy, price target $88

Questions about Citigroup and THC

What is Citigroup's price target for THC?: Citigroup's latest stated price target for Tenet Healthcare Corporation (THC) is $96, from its action on Jan 10, 2022.
What is Citigroup's rating on THC?: Citigroup rates THC Buy, a bullish rating, as of Jan 10, 2022.
When did Citigroup last change its view on THC?: On Jan 10, 2022, Citigroup resumes coverage at Buy, price target $91 to $96.

More THC rating histories

All Citigroup ratings THC news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.